Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value.

AL, light chain amyloidosis ATTR, transthyretin amyloidosis ATTR-v, variant transthyretin ATTR-wt, wild-type transthyretin AUC, area under the curve BNP, B-type natriuretic peptide CA, cardiac amyloidosis CMR, cardiac magnetic resonance CV, cardiovascular ECG, electrocardiogram LQRSV, low QRS voltages LV, left ventricle LVEDD, left ventricular end-diastolic diameter NAC, National Amyloidosis Centre NT-proBNP, N-terminal pro–B-type natriuretic peptide NYHA, New York Heart Association ROC, receiver-operating characteristic RV, right ventricular TAPSE, tricuspid annulus peak systolic excursion cardiac amyloidosis echocardiography electrocardiography low QRS voltages prognostic significance risk stratification

Journal

JACC. CardioOncology
ISSN: 2666-0873
Titre abrégé: JACC CardioOncol
Pays: United States
ID NLM: 101761697

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 09 07 2022
revised: 27 08 2022
accepted: 28 08 2022
entrez: 29 11 2022
pubmed: 30 11 2022
medline: 30 11 2022
Statut: epublish

Résumé

Low QRS voltages (LQRSVs) are a common electrocardiographic feature in patients with light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) cardiac amyloidosis (CA). The aim of this study was to identify clinical and echocardiographic correlates of LQRSV and to investigate their prognostic significance in patients with CA. This was a multicenter, retrospective study performed in 6 CA referral centers including consecutive patients with AL and ATTR CA. LQRSVs were defined as a QRS amplitude ≤5 mm (0.5 mV) in all peripheral leads. The study outcome was cardiovascular (CV) mortality. Overall, 411 (AL CA: n = 120, ATTR CA: n = 291) patients were included. LQRSVs were present in 66 (55%) patients with AL CA and 103 (35%) with ATTR CA ( LQRSVs are common but not ubiquitous in CA; they are more frequent in AL CA than in ATTR CA. LQRSVs reflect an advanced disease stage and independently predict CV death. In ATTR CA, LQRSVs can provide incremental prognostic accuracy over the NAC staging system in patients with intermediate risk.

Sections du résumé

Background UNASSIGNED
Low QRS voltages (LQRSVs) are a common electrocardiographic feature in patients with light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) cardiac amyloidosis (CA).
Objectives UNASSIGNED
The aim of this study was to identify clinical and echocardiographic correlates of LQRSV and to investigate their prognostic significance in patients with CA.
Methods UNASSIGNED
This was a multicenter, retrospective study performed in 6 CA referral centers including consecutive patients with AL and ATTR CA. LQRSVs were defined as a QRS amplitude ≤5 mm (0.5 mV) in all peripheral leads. The study outcome was cardiovascular (CV) mortality.
Results UNASSIGNED
Overall, 411 (AL CA: n = 120, ATTR CA: n = 291) patients were included. LQRSVs were present in 66 (55%) patients with AL CA and 103 (35%) with ATTR CA (
Conclusions UNASSIGNED
LQRSVs are common but not ubiquitous in CA; they are more frequent in AL CA than in ATTR CA. LQRSVs reflect an advanced disease stage and independently predict CV death. In ATTR CA, LQRSVs can provide incremental prognostic accuracy over the NAC staging system in patients with intermediate risk.

Identifiants

pubmed: 36444225
doi: 10.1016/j.jaccao.2022.08.007
pii: S2666-0873(22)00385-4
pmc: PMC9700257
doi:

Types de publication

Journal Article

Langues

eng

Pagination

458-470

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Références

Eur J Prev Cardiol. 2022 May 27;29(8):1177-1187
pubmed: 33624098
Circulation. 2014 May 6;129(18):1840-9
pubmed: 24563469
ESC Heart Fail. 2022 Jun;9(3):1731-1739
pubmed: 35191205
Heart Fail Rev. 2015 Mar;20(2):117-24
pubmed: 25758359
Circ Res. 2021 May 14;128(10):1554-1575
pubmed: 33983835
Ann Noninvasive Electrocardiol. 2011 Jan;16(1):25-9
pubmed: 21251130
Circulation. 2009 Sep 29;120(13):1203-12
pubmed: 19752327
J Intern Med. 2021 Mar;289(3):268-292
pubmed: 32929754
J Am Heart Assoc. 2017 Jan 22;6(1):
pubmed: 28111363
Am J Cardiol. 2005 Feb 15;95(4):535-7
pubmed: 15695149
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Eur J Heart Fail. 2022 Jul;24(7):1227-1236
pubmed: 35509181
JACC CardioOncol. 2021 Aug 17;3(4):522-533
pubmed: 34729524
Circ Res. 2004 Apr 30;94(8):1008-10
pubmed: 15044325
JACC Cardiovasc Imaging. 2020 Apr;13(4):909-920
pubmed: 31864973
Blood. 2020 Dec 3;136(23):2620-2627
pubmed: 33270858
Stat Med. 2013 Dec 30;32(30):5381-97
pubmed: 24027076
EMBO Mol Med. 2014 Oct 15;6(11):1493-507
pubmed: 25319546
J Am Coll Cardiol. 2018 Jun 26;71(25):2919-2931
pubmed: 29929616
Ann Noninvasive Electrocardiol. 2013 May;18(3):271-80
pubmed: 23714086
Heart Rhythm. 2013 Jan;10(1):70-7
pubmed: 22975421
Cardiovasc Res. 2022 Aug 05;:
pubmed: 35929637
Lancet. 2016 Jun 25;387(10038):2641-2654
pubmed: 26719234
Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1321-1360
pubmed: 27422899
Eur Heart J. 2021 Apr 21;42(16):1554-1568
pubmed: 33825853
Eur J Heart Fail. 2007 Jun-Jul;9(6-7):617-24
pubmed: 17350331
Am J Cardiol. 2007 Mar 1;99(5):711-3
pubmed: 17317378
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Int J Cardiol. 2016 Jul 1;214:477-81
pubmed: 27093686
J Am Coll Cardiol. 2004 Feb 4;43(3):410-5
pubmed: 15013123
Eur Heart J. 2019 Dec 1;40(45):3699-3706
pubmed: 31111153
Stat Med. 2011 Jan 15;30(1):11-21
pubmed: 21204120
JACC CardioOncol. 2021 Oct 19;3(4):537-546
pubmed: 34729526
J Stat Softw. 2011 Mar;39(5):1-13
pubmed: 27065756
JACC CardioOncol. 2021 Oct 19;3(4):467-487
pubmed: 34729520
Circulation. 2007 Mar 13;115(10):1306-24
pubmed: 17322457
JACC CardioOncol. 2021 Oct 19;3(4):488-505
pubmed: 34729521
J Clin Oncol. 2012 Mar 20;30(9):989-95
pubmed: 22331953
Am J Cardiol. 2014 Oct 1;114(7):1089-93
pubmed: 25212550
Amyloid. 2016 Sep;23(3):194-202
pubmed: 27647161
Eur Heart J. 2018 Aug 7;39(30):2799-2806
pubmed: 29048471
Am Heart J. 1997 Dec;134(6):994-1001
pubmed: 9424057
J Am Coll Cardiol. 2005 Sep 20;46(6):1076-84
pubmed: 16168294

Auteurs

Alberto Cipriani (A)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Laura De Michieli (L)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Aldostefano Porcari (A)

Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy.

Luca Licchelli (L)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Giulio Sinigiani (G)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Giacomo Tini (G)

Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.

Mattia Zampieri (M)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Eugenio Sessarego (E)

Department of Internal Medicine, University of Genova, Genova, Italy.

Alessia Argirò (A)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Carlo Fumagalli (C)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Monica De Gaspari (M)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Roberto Licordari (R)

Department of Cardiology, University of Messina, Messina, Italy.

Domitilla Russo (D)

Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.

Gianluca Di Bella (G)

Department of Cardiology, University of Messina, Messina, Italy.

Federico Perfetto (F)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Cardiomyopathy Unit, Careggi University Hospital, University of Florence, Florence, Italy.

Camillo Autore (C)

Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.

Beatrice Musumeci (B)

Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.

Marco Canepa (M)

Department of Internal Medicine, University of Genova, Genova, Italy.
Cardiovascular Unit, Department of Internal Medicine, University of Genova, Ospedale Policlinico San Martino Istituto Ricovero e Cura a Carattere Scientifico, Genova, Italy.

Marco Merlo (M)

Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy.

Gianfranco Sinagra (G)

Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy.

Dario Gregori (D)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Sabino Iliceto (S)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Martina Perazzolo Marra (M)

Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Francesco Cappelli (F)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
Cardiomyopathy Unit, Careggi University Hospital, University of Florence, Florence, Italy.

Claudio Rapezzi (C)

Cardiothoracic Department, University of Ferrara, Ferrara, Italy.
Maria Cecilia Hospital, Gruppo Villa Maria Care and Research, Cotignola, Ravenna, Italy.

Classifications MeSH